Tonix Pharmaceuticals Uplists to Nasdaq Global Select Market

summarizeSummary

Tonix Pharmaceuticals Holding Corp. announced its common stock has been approved for transfer to the Nasdaq Global Select Market, signifying compliance with higher financial and corporate governance standards.

check_boxKey Events

• Uplisting to Nasdaq Global Select Market

  Tonix Pharmaceuticals received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market.

• Effective Date

  Trading on the Nasdaq Global Select Market is expected to commence at the open of market on March 3, 2026, under the existing ticker symbol 'TNXP'.

• Enhanced Visibility and Standards

  The uplisting reflects compliance with Nasdaq Global Select Market's higher financial and corporate governance standards, aiming to enhance visibility among institutional investors, improve liquidity, and broaden market recognition.

auto_awesomeAnalysis

Tonix Pharmaceuticals' move to the Nasdaq Global Select Market is a significant corporate governance milestone. This uplisting indicates the company meets higher financial and corporate governance standards, which can enhance its appeal to institutional investors and potentially improve stock liquidity. For a biotechnology company, achieving this tier can boost its reputation and visibility within the investment community, signaling a more mature and stable operational profile.